IL269895A - - Google Patents
Info
- Publication number
- IL269895A IL269895A IL26989519A IL26989519A IL269895A IL 269895 A IL269895 A IL 269895A IL 26989519 A IL26989519 A IL 26989519A IL 26989519 A IL26989519 A IL 26989519A IL 269895 A IL269895 A IL 269895A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GBGB1706404.9A GB201706404D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GBGB1706452.8A GB201706452D0 (en) | 2017-04-24 | 2017-04-24 | Method of treatment |
| PCT/EP2018/060241 WO2018193122A1 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL269895A true IL269895A (https=) | 2019-12-31 |
| IL269895B1 IL269895B1 (en) | 2024-02-01 |
| IL269895B2 IL269895B2 (en) | 2024-06-01 |
Family
ID=62235916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL269895A IL269895B2 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11730792B2 (https=) |
| EP (2) | EP3612208B1 (https=) |
| JP (2) | JP7209637B2 (https=) |
| KR (1) | KR102656199B1 (https=) |
| CN (1) | CN110896606B (https=) |
| AU (1) | AU2018253962B2 (https=) |
| CA (1) | CA3059657A1 (https=) |
| DK (1) | DK3612208T5 (https=) |
| ES (1) | ES2945433T3 (https=) |
| IL (1) | IL269895B2 (https=) |
| PL (1) | PL3612208T3 (https=) |
| WO (1) | WO2018193122A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2018193120A1 (en) * | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of cicatrising eye inflammatory disorders |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US11730792B2 (en) | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US20220370556A1 (en) * | 2019-09-27 | 2022-11-24 | Volution Immuno Pharmaceuticals Sa | Method of Treatment |
| GB202218084D0 (en) * | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| EP1629098B1 (en) | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
| EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007095230A2 (en) * | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
| PL2061501T3 (pl) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| AU2008228247A1 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| SI2173890T1 (sl) * | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2011056972A2 (en) * | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| CA2737924A1 (en) * | 2008-10-06 | 2010-04-15 | Joshua Robert Schultz | Methods of treating inflammation |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| CA2766565A1 (en) * | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| JP5840623B2 (ja) | 2010-01-08 | 2016-01-06 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 気道のウイルス感染症の治療に用いるｅｖ５７６ |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| GB201410031D0 (en) * | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CA2988313A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| WO2016201301A1 (en) * | 2015-06-12 | 2016-12-15 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| US20170073399A1 (en) * | 2015-09-11 | 2017-03-16 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2018193120A1 (en) | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of cicatrising eye inflammatory disorders |
| US11730792B2 (en) | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
-
2018
- 2018-04-20 US US16/603,352 patent/US11730792B2/en active Active
- 2018-04-20 WO PCT/EP2018/060241 patent/WO2018193122A1/en not_active Ceased
- 2018-04-20 CN CN201880041710.5A patent/CN110896606B/zh active Active
- 2018-04-20 CA CA3059657A patent/CA3059657A1/en active Pending
- 2018-04-20 ES ES18726731T patent/ES2945433T3/es active Active
- 2018-04-20 EP EP18726731.5A patent/EP3612208B1/en active Active
- 2018-04-20 AU AU2018253962A patent/AU2018253962B2/en active Active
- 2018-04-20 IL IL269895A patent/IL269895B2/en unknown
- 2018-04-20 PL PL18726731.5T patent/PL3612208T3/pl unknown
- 2018-04-20 KR KR1020197031711A patent/KR102656199B1/ko active Active
- 2018-04-20 DK DK18726731.5T patent/DK3612208T5/da active
- 2018-04-20 EP EP23166056.4A patent/EP4275696A1/en active Pending
- 2018-04-20 JP JP2019556794A patent/JP7209637B2/ja active Active
-
2023
- 2023-01-10 JP JP2023001554A patent/JP7600278B2/ja active Active
- 2023-06-09 US US18/332,191 patent/US20240009270A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3612208T5 (da) | 2024-09-02 |
| JP7600278B2 (ja) | 2024-12-16 |
| JP7209637B2 (ja) | 2023-01-20 |
| PL3612208T3 (pl) | 2023-07-24 |
| JP2020517627A (ja) | 2020-06-18 |
| US20240009270A1 (en) | 2024-01-11 |
| DK3612208T3 (da) | 2023-05-08 |
| KR20190139233A (ko) | 2019-12-17 |
| IL269895B1 (en) | 2024-02-01 |
| IL269895B2 (en) | 2024-06-01 |
| ES2945433T3 (es) | 2023-07-03 |
| KR102656199B1 (ko) | 2024-04-09 |
| JP2023040169A (ja) | 2023-03-22 |
| AU2018253962A1 (en) | 2019-10-31 |
| CN110896606A (zh) | 2020-03-20 |
| EP3612208A1 (en) | 2020-02-26 |
| CN110896606B (zh) | 2024-07-16 |
| EP3612208B1 (en) | 2023-04-05 |
| US11730792B2 (en) | 2023-08-22 |
| CA3059657A1 (en) | 2018-10-25 |
| EP4275696A1 (en) | 2023-11-15 |
| AU2018253962B2 (en) | 2024-12-05 |
| WO2018193122A1 (en) | 2018-10-25 |
| US20200113971A1 (en) | 2020-04-16 |